CA3250917A1 - Induction of alpha-synuclein-specific tolerance by MHC 1B as a novel treatment for Parkinson's disease - Google Patents
Induction of alpha-synuclein-specific tolerance by MHC 1B as a novel treatment for Parkinson's diseaseInfo
- Publication number
- CA3250917A1 CA3250917A1 CA3250917A CA3250917A CA3250917A1 CA 3250917 A1 CA3250917 A1 CA 3250917A1 CA 3250917 A CA3250917 A CA 3250917A CA 3250917 A CA3250917 A CA 3250917A CA 3250917 A1 CA3250917 A1 CA 3250917A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- alpha
- recombinant polypeptide
- domain
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/605—MHC molecules or ligands thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Psychology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22164123.6A EP4249506A1 (en) | 2022-03-24 | 2022-03-24 | Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease |
| EP22164123.6 | 2022-03-24 | ||
| PCT/EP2023/057682 WO2023180548A1 (en) | 2022-03-24 | 2023-03-24 | Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3250917A1 true CA3250917A1 (en) | 2023-09-28 |
Family
ID=81384775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3250917A Pending CA3250917A1 (en) | 2022-03-24 | 2023-03-24 | Induction of alpha-synuclein-specific tolerance by MHC 1B as a novel treatment for Parkinson's disease |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250205321A1 (enExample) |
| EP (2) | EP4249506A1 (enExample) |
| JP (1) | JP2025514872A (enExample) |
| KR (1) | KR20240162549A (enExample) |
| CN (1) | CN119317639A (enExample) |
| AU (1) | AU2023238805A1 (enExample) |
| CA (1) | CA3250917A1 (enExample) |
| CL (1) | CL2024002724A1 (enExample) |
| CO (1) | CO2024012329A2 (enExample) |
| IL (1) | IL314741A (enExample) |
| MX (1) | MX2024011665A (enExample) |
| WO (1) | WO2023180548A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025061918A1 (en) * | 2023-09-22 | 2025-03-27 | Julius-Maximilians-Universität Würzburg | Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3063959A1 (en) | 2017-05-23 | 2018-11-29 | Julius-Maximilians-Universitat Wurzburg | Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulation |
-
2022
- 2022-03-24 EP EP22164123.6A patent/EP4249506A1/en not_active Withdrawn
-
2023
- 2023-03-24 EP EP23715474.5A patent/EP4499682A1/en active Pending
- 2023-03-24 JP JP2024556456A patent/JP2025514872A/ja active Pending
- 2023-03-24 IL IL314741A patent/IL314741A/en unknown
- 2023-03-24 CN CN202380029745.8A patent/CN119317639A/zh active Pending
- 2023-03-24 MX MX2024011665A patent/MX2024011665A/es unknown
- 2023-03-24 KR KR1020247034476A patent/KR20240162549A/ko active Pending
- 2023-03-24 AU AU2023238805A patent/AU2023238805A1/en active Pending
- 2023-03-24 WO PCT/EP2023/057682 patent/WO2023180548A1/en not_active Ceased
- 2023-03-24 US US18/849,009 patent/US20250205321A1/en active Pending
- 2023-03-24 CA CA3250917A patent/CA3250917A1/en active Pending
-
2024
- 2024-09-11 CL CL2024002724A patent/CL2024002724A1/es unknown
- 2024-09-11 CO CONC2024/0012329A patent/CO2024012329A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4499682A1 (en) | 2025-02-05 |
| AU2023238805A1 (en) | 2024-07-18 |
| WO2023180548A1 (en) | 2023-09-28 |
| CL2024002724A1 (es) | 2025-02-14 |
| KR20240162549A (ko) | 2024-11-15 |
| JP2025514872A (ja) | 2025-05-12 |
| IL314741A (en) | 2024-10-01 |
| US20250205321A1 (en) | 2025-06-26 |
| CN119317639A (zh) | 2025-01-14 |
| EP4249506A1 (en) | 2023-09-27 |
| CO2024012329A2 (es) | 2024-09-30 |
| MX2024011665A (es) | 2024-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shin et al. | CD8α− dendritic cells induce antigen-specific T follicular helper cells generating efficient humoral immune responses | |
| CN102083979B (zh) | Hbv表位反应性外源t细胞受体(tcr)及其用途 | |
| JP2020517308A (ja) | Ｔｃｒ及びペプチド | |
| CN112004924A (zh) | 增强treg细胞抑制特性的方法 | |
| JPH10504284A (ja) | 抗原パルス化樹状細胞によるｉｎ ｖｉｖｏ Ｔ細胞活性化法 | |
| US20230416338A1 (en) | Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulation | |
| WO2019091347A1 (zh) | 识别乙肝病毒(hbv)表面抗原s183-91表位的tcr及其用途 | |
| WO2016095783A1 (zh) | 识别eb病毒短肽的t细胞受体 | |
| JP2016539635A (ja) | 抗原特異的調節性ｔ細胞の誘導方法 | |
| Peng et al. | Novel vaccines for the treatment of chronic HBV infection based on mycobacterial heat shock protein 70 | |
| US20250205321A1 (en) | Mhc ib-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease | |
| WO2020145222A1 (ja) | 新規ネオアンチゲン及びそれらを用いたがん免疫治療薬 | |
| Roe et al. | Targeting antigens to CD180 but not CD40 programs immature and mature B cell subsets to become efficient APCs | |
| Bursch et al. | Langerhans cells are not required for the CD8 T cell response to epidermal self-antigens | |
| Lyu et al. | A novel and simple method to produce large amounts of recombinant soluble peptide/major histocompatibility complex monomers for analysis of antigen-specific human T cell receptors | |
| JP2022546106A (ja) | Ｅｂｖ－由来抗原に特異的なｔｃｒ構築物 | |
| US20250222083A1 (en) | Mhc ib-mediated myelin-specific immunosuppression as a novel treatment for multiple sclerosis and mog antibody disease | |
| JP2021511054A5 (enExample) | ||
| EP4249062A1 (en) | Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo | |
| WO2025061918A1 (en) | Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease | |
| EA052620B1 (ru) | ОПОСРЕДОВАННАЯ MHC 1b ИНДУКЦИЯ СПЕЦИФИЧЕСКОЙ ДЛЯ АЛЬФАСИНУКЛЕИНА ТОЛЕРАНТНОСТИ В КАЧЕСТВЕ НОВОГО ЛЕЧЕНИЯ ПРОТИВ БОЛЕЗНИ ПАРКИНСОНА | |
| JP2023536100A (ja) | 代替の翻訳開始および翻訳停止に由来する多機能免疫グロブリンフォールドポリペプチド | |
| Fehlner et al. | Murine T cell responses to melittin and its analogs | |
| WO2008126940A1 (ja) | 新規ｔ細胞 | |
| KR20240052028A (ko) | 면역 제어법, 면역 제어용 핵산 조성물 및 그 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240805 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20240805 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241211 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241211 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20241211 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20241212 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20241212 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250307 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250317 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250317 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250317 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260210 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260210 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260317 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260317 |